Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
10/8/26
Agios Pharmaceuticals (AGIO)
Thursday
5:09 AM
ThesisAgios Pharmaceuticals: the setup is constructive — Phase 2/3 clinical trial data readouts for pipeline programs (thalassemia, sickle cell indications for mitapivat)
growth - Speculative biotech investors seeking asymmetric returns from clinical catalysts and regulatory approvals.
Rising rates negatively impact valuation multiples for pre-profitable biotech (higher discount rates on distant cash flows) and increase…
Watch on earnings: PYRUKYND quarterly prescription volume (TRx) and new patient starts (NBRx) from IQVIA data, Clinical trial enrollment rates and data readout timelines for thalassemia and sickle cell programs, Cash and marketable securities balance relative to quarterly burn rate.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $183M to $351M as phase 2/3 clinical trial data readouts for pipeline programs (thalassemia, sickle cell indications for mitapivat).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
